Clinical trials: NSTEMI
Acute Non-ST Elevation Myocardial Infarction
DLBS1033 for Acute NSTEMI Without Early Coronary Revascularization
This is a prospective, randomized, double-blind, double-dummy, and controlled study of DLBS1033 in the management of acute non-ST elevation myocardial infarction (NSTEMI) without early coronary revascularization.
- Trial name
- NCT02146664
- Testing
- DLBS1033
- Where
- 2 sites in Indonesia
- Sponsor
- Dexa Medica Group
Acute Coronary Syndromes
Investigation of the Biomarker Copeptin in Patients With Acute Myocardial Infarction
While troponin is not detectable until several hours after an Acute Myocardial Infarction (AMI), copeptin is expected to be elevated very early after an AMI.
- Trial name
- CHOPIN (NCT00952744)
- Where
- 11 sites in United States
- Volunteers
- 2,071 people
- Sponsor
- Brahms AG
Acute Myocardial Infarction, Non-ST Elevation Myocardial Infarction
Impact of Cardiac Rehabilitation Programs on Left Ventricular Remodeling After Acute Myocardial Infarction - the REHAB Trial
The aim of REHAB trial is to investigate the impact of early mobilization after AMI in reducing left ventricular remodeling, as assessed by cardiac magnetic resonance imaging.
- Conditions
- Acute Myocardial Infarction, Non-ST Elevation Myocardial Infarction, Systemic Inflammation, Ventricular Remodeling
- Trial name
- NCT04161378
- Testing
- Cardiac imaging, Laboratory analysis
- Where
- Romania
- Volunteers
- 100 people
- Sponsor
- Cardio Med Medical Center
Non-ST Segment Elevation Myocardial Infarction
Anfibatide Phase Ib-IIa Clinical Trial
Investigate the safety and efficacy of Anfibatide in non-ST segment myocardial infarction patients
- Trial name
- NCT01585259
- Testing
- Anfibatide
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Lee's Pharmaceutical Limited
Unstable Angina, Coronary Atherosclerosis
Serp-1 for the Treatment of Acute Coronary Syndrome
Males and females aged 18-80 years who present with ACS (unstable angina and non ST-elevation MI) defined as one or more episodes of angina lasting at least 5 minutes in the last 24 hours before admission and greater than 0.05 mV…
- Conditions
- Unstable Angina, Coronary Atherosclerosis, Coronary Restenosis
- Trial name
- NCT00243308
- Testing
- Serine proteinase-1 (Serp-1)
- Where
- 8 sites in United States, Canada
- Volunteers
- 72 people
- Sponsor
- Viron Therapeutics Inc
Cost Sharing, Acute Coronary Syndrome
Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study
Current patterns of P2Y12 receptor inhibitor use provide an excellent opportunity to test the impact of copayment reduction on clinician choice of medication, patient adherence, and clinical outcomes.
- Trial name
- ARTEMIS (NCT02406677)
- Testing
- Study voucher card
- Where
- 272 sites in United States, Puerto Rico
- Volunteers
- 11,001 people
- Sponsor
- AstraZeneca
Acute Coronary Syndrome
PiCSO in ACS Study
The purpose of this research study is to find out whether PICSO (Pressure Controlled Coronary Sinus Occlusion), given concomitant to (NSTEMI) or following (STEMI) primary PCI and stenting, can improve final infarct size and…
- Trial name
- NCT02197325
- Testing
- PICSO
- Where
- 4 sites in United Kingdom
- Volunteers
- 99 people
- Sponsor
- Miracor Medical SA
Coronary Artery Disease, Stable Angina
BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM
Prospective, multi-center, registry designed to enrol up to 2,000 patients in up to 35 International centers. All patients will receive a BioMatrix AlphaTM stent as per clinical practice and will be followed for 2 years for data…
- Conditions
- Coronary Artery Disease, Stable Angina, Ischemia, Acute Coronary Syndrome
- Trial name
- NCT02871622
- Testing
- BioMatrix AlphaTM
- Where
- United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Biosensors Europe SA
Coronary Artery Disease
BIOFLOW III Satellite-ELADIS Orsiro Stent System
This registry is a clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES).
- Trial name
- NCT02029092
- Where
- 14 sites in Spain
- Volunteers
- 404 people
- Sponsor
- C.E.M. Biotronik, S.A.
Acute Coronary Syndrome
Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
The purpose of this trial is to learn about the effects of inclisiran in people with serious heart conditions (acute coronary syndromes), when this treatment is started early after hospital admission.
- Trial name
- ACS (NCT07102628)
- Testing
- Inclisiran
- Where
- 69 sites in Argentina, Australia and 12 more
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2, NSTEMI - Non-ST Segment Elevation MI
Incidence of Major Cardiovascular Events in Diabetic Patients With ACS Undergoing Coronary Angioplasty and Treated With Clopidogrel 150 mg Versus 75 mg
Acute Coronary Syndrome (ACS) is triggered by the rupture of an atherosclerotic plaque that results in a platelet aggregation reaction in the coronary artery.
- Conditions
- Diabetes Mellitus, Type 2, NSTEMI - Non-ST Segment Elevation MI, Coronary Angioplasty
- Trial name
- IDASCOP 1 (NCT03329261)
- Testing
- Clopidogrel
- Where
- Tunisia
- Volunteers
- 167 people
- Sponsor
- Laboratoires Teriak
Heart Attack, Cardiac Event
Mobile Advanced Multi-Parameter Reporting in Patients Wearing a Novel Device: Utilization During Cardiac Rehabilitation
Advanced remote multi-parameter reporting during cardiac rehabilitation (MAPS-III). The primary purpose of this observational study is to collect baseline information of cardiac rehabilitation usage in the US for post-myocardial…
- Conditions
- Heart Attack, Cardiac Event, Cardiac Disease, Cardiac Infarct
- Trial name
- MAPS-III (NCT05957172)
- Testing
- ZOLL Arrhythmia Management System
- Sponsor
- Zoll Medical Corporation
Coronary Stenosis, Acute Coronary Syndrome
Systemic, Pancoronary and Local Coronary Vulnerability
The aim of the VIP study is to investigate the impact of vulnerability markers (inflammatory serum biomarkers for systemic vulnerability, coronary shear stress and vulnerability mapping for pancoronary vulnerability, and…
- Conditions
- Coronary Stenosis, Acute Coronary Syndrome, Acute Myocardial Infarction, Atheromatous Plaques
- Trial name
- VIP (NCT03606330)
- Testing
- Cardiac imaging tests, Venous blood sample collection
- Where
- Romania
- Volunteers
- 100 people
- Sponsor
- Cardio Med Medical Center
STEMI, NSTEMI
Assessment of Individual Risk of Cardiovascular Events by Platelet FcGammaRIIa
This is a Prospective, Observational Multicenter Non-Interventional Cohort Study. The primary objective is to determine whether platelet expression of FcγRIIa is associated with risk of myocardial infarction (MI), stroke and…
- Trial name
- NCT05175261
- Testing
- Prolocor pFCG test
- Where
- United States
- Volunteers
- 764 people
- Sponsor
- Prolocor, Inc
Coronary Artery Diseases
BIOFLOW-III VIP Russia Registry Orsiro Stent System
Clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES). Along with it, an explanatory (hypothesis-finding) problem will be investigated, whether the patient's body…
- Trial name
- NCT02247492
- Where
- 7 sites in Russia
- Volunteers
- 200 people
- Sponsor
- Biotronik Russia
Acute Coronary Syndrome (ACS)
Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL
CTQJ230A1US13 is a randomized, double-blind, placebo-controlled, multicenter phase IIIb study designed to evaluate the efficacy, safety, tolerability, and coronary plaque effects of early pelacarsen (TQJ230) initiation in…
- Trial name
- NCT07625306
- Testing
- Pelacarsen
- Sponsor
- Novartis Pharmaceuticals
Coronary Artery Diseases
BIOFLOW-III UK Satellite Registry Orsiro Stent System
Clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES). 500 subjects will be enrolled in this registry.
- Trial name
- NCT02257710
- Testing
- Orsiro
- Where
- 4 sites in United Kingdom
- Volunteers
- 500 people
- Sponsor
- Biotronik UK Ltd.
Coronary Artery Disease
Advanced NanoTherapies Dual-API DCB to Treat De-Novo Lesions in Patients With Symptomatic Coronary Artery Disease
This prospective, single-arm, multi-center, safety and feasibility first-in-human study will evaluate the safety and feasibility of the SirPlux Duo™ Dual-API Coated PTCA Balloon Catheter to treat de-novo lesions between ≥2.0 and…
- Trial name
- ADVANCE-DCB (NCT05521542)
- Testing
- SirPlux Duo™ Dual-API Coated PTCA Balloon Catheter
- Where
- 5 sites in Australia, Dominican Republic and 1 more
- Volunteers
- 28 people
- Sponsor
- Advanced NanoTherapies
Coronary Stenosis, Coronary Disease
IonMAN Trial- First in Human Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System
This is a prospective, multi-center, single-arm, open-label, First in Human clinical trial to provide preliminary evidence for the safety and efficacy of the novel IoNIR stent system.
- Conditions
- Coronary Stenosis, Coronary Disease, Non-ST Elevated Myocardial Infarction, Cardiovascular Diseases
- Trial name
- IonMAN (NCT05364697)
- Testing
- IoNIR Ridaforolimus-Eluting Coronary Stent System
- Where
- 4 sites in Brazil, Israel
- Volunteers
- 60 people
- Sponsor
- Medinol Ltd.
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III Austria Satellite Registry
This registry is a clinical post-market evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES).
- Trial name
- NCT01667016
- Where
- 8 sites in Austria
- Volunteers
- 305 people
- Sponsor
- Biotronik Vertriebs-GmbH